Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Stuart Weinzimer, Kellee Miller, Roy k Beck, Dongyuan Xing, Rosanna Fiallo-Scharer, Lisa K Gilliam, Craig Kollman, Lori Laffel, Nelly Mauras, Katrina Ruedy, William Tamborlane, Eva Tsalikian, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Stuart Weinzimer, Kellee Miller, Roy k Beck, Dongyuan Xing, Rosanna Fiallo-Scharer, Lisa K Gilliam, Craig Kollman, Lori Laffel, Nelly Mauras, Katrina Ruedy, William Tamborlane, Eva Tsalikian

Abstract

Objective: To determine whether continuous glucose monitoring (CGM) is effective in the management of type 1 diabetes when implemented in a manner that more closely approximates clinical practice.

Research design and methods: After completion of a 6-month randomized controlled trial (RCT) evaluating CGM in children, adolescents, and adults with type 1 diabetes, CGM was initiated in the trial's control group with less intensive training and follow-up than was included in the RCT. Subjects had an outpatient training session, two follow-up phone calls, and outpatient visits at 1, 4, 13, and 26 weeks. For subjects with baseline A1C > or =7.0%, the primary outcome was change in A1C at 6 months.

Results: CGM use decreased from a median of 7.0 days/week in the first month in the > or =25-year-old group, 6.3 days/week in the 15-24 year olds, and 6.8 days/week in the 8-14 year olds to 6.5, 3.3, and 3.7 days/week in the 6th month, respectively (P < 0.001 for each age-group). Among subjects with baseline A1C > or =7.0%, CGM use was associated with A1C reduction after 6 months (P = 0.02 adjusted for age-group). Severe hypoglycemia decreased from 27.7 events per 100 person-years in the 6-month control phase of the RCT to 15.0 events per 100 person-years in the 6-month follow-up CGM phase (P = 0.08).

Conclusions: Frequent use of CGM in a clinical care setting may improve A1C and reduce episodes of hypoglycemia. However, sustained frequent use of CGM is less likely in children and adolescents than in adults.

Trial registration: ClinicalTrials.gov NCT00406133.

Figures

Figure 1
Figure 1
CGM use over 6 months according to age-group. Box plots indicating sensor use in each 4-week time period for the 212 subjects who completed the study (two subjects who did not complete the study are not included) are shown. The top and bottom of the boxes denote the 25th and 75th percentiles, the line represents the median, and the dot represents the mean. The numbers of subjects who did not use CGM during a 4-week period are indicated below each box plot (these data are included in each box plot).

References

    1. Resnick HE, Foster GL, Bardsley J, Ratner RE: Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531– 537
    1. Bode BW, Schwartz S, Stubbs HA, Block JE: Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 2005; 28: 2361– 2366
    1. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001; 24: 1858– 1862
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464– 1476
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009; 32: 1947– 1953
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32: 1378– 1383
    1. JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther 2008; 10: 310– 321
    1. Diabetes Research In Children Network (DirecNet) Study Group. Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the Freestyle Navigator). Pediatr Diabetes 2008; 9: 142– 147
    1. Gibb I, Parnham A, Fonfrède M, Lecock F: Multicenter evaluation of Tosoh glycohemoglobin analyzer. Clin Chem 1999; 45: 1833– 1841
    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977– 986
    1. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730– 2732
    1. Messer L, Ruedy K, Xing D, Coffey J, Englert K, Caswell K, Ives B: Educating families on real time continuous glucose monitoring: the DirecNet navigator pilot study experience. Diabetes Educ 2009; 35: 124– 135
    1. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W: Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 1997; 20: 1655– 1658

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe